从资金流向上来看，当日医疗服务板块主力资金净流出2.28亿元，游资资金净流入1.68亿元，散户资金 净流入5964.42万元。医疗服务板块个股资金流向见下表： 以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。 证券之星消息，9月16日医疗服务板块较上一交易日上涨0.29%，诚达药业领涨。当日上证指数报收于 3861.87，上涨0.04%。深证成指报收于13063.97，上涨0.45%。医疗服务板块个股涨跌见下表： | 代码 | 名称 | 收盘价 | 涨跌幅 | 成交量(手) | 成交额(元) | | | --- | --- | --- | --- | --- | --- | --- | | 301201 | 诚达药业 | 33.32 | 15.25% | 15.71万 | | 5.08亿 | | 002622 | 皓宸医疗 | 4.25 | 10.10% | 99.32万 | | 4.09亿 | | 002172 | 澳洋健康 | 4.73 | 10.00% | 8.75万 | | 4139.70万 | | 688073 | 毕得医药 ...

Group 1 - The stock price of Haocen Medical (002622) closed at 3.94 yuan on September 3, 2025, with an increase of 3.96% and a trading volume of 706,500 hands, resulting in a transaction amount of 274 million yuan [1] - On September 3, 2025, the net inflow of main funds was 8.9685 million yuan, accounting for 3.27% of the total transaction amount, while retail investors experienced a net outflow of 36.7847 million yuan, representing 13.42% of the total transaction amount [1] - The company's main business includes oral medical services and the research, production, and sales of permanent magnet switches and complete sets of high and low voltage switchgear [2] Group 2 - Haocen Medical's total market value is 3.31 billion yuan, with a net asset of 408 million yuan and a net profit of -23.7511 million yuan, ranking 37th, 39th, and 36th respectively in the medical service industry [2] - The company's revenue for the first half of 2025 was 314 million yuan, a year-on-year decrease of 17.9%, while the net profit attributable to shareholders was -23.7511 million yuan, a year-on-year decline of 4391.18% [2] - The gross profit margin of Haocen Medical is 43.16%, which is higher than the industry average of 35.92%, while the net profit margin is -11.04%, significantly lower than the industry average of 3.8% [2]

Core Points - The company has released its 2025 semi-annual report, which provides insights into its operational results, financial status, and future development plans [1] - The board of directors and the supervisory board have both approved the semi-annual report, confirming that the content is true, accurate, and complete [12][13] Company Overview - The company is named Haocen Medical Technology Co., Ltd., with the stock code 002622 [1] - The company has not changed its controlling shareholder during the reporting period [5] Financial Information - The company plans not to distribute cash dividends, issue bonus shares, or increase capital from reserves during the reporting period [3] - The company has confirmed that there are no preferred shareholders or changes in preferred shareholder holdings during the reporting period [6] Meeting Details - The fifth board of directors' fifteenth meeting was held on August 28, 2025, with all directors present [2][7] - The supervisory board's fifteenth meeting was also held on August 28, 2025, with all supervisors present [12][13] Document Availability - The full content of the 2025 semi-annual report can be accessed on the designated information disclosure website [9][14]

Financial Performance - The company's total revenue for the first half of 2025 was 314 million yuan, ranking 39th among disclosed peers, representing a decrease of 68.37 million yuan or 17.90% year-on-year [1] - The net profit attributable to shareholders was -23.75 million yuan, ranking 44th among disclosed peers, a decrease of 24.30 million yuan or 4391.18% year-on-year [1] - The net cash flow from operating activities was -27.59 million yuan, ranking 43rd among disclosed peers, a decrease of 34.59 million yuan or 494.15% year-on-year [1] Financial Ratios - The latest debt-to-asset ratio was 71.73%, ranking 47th among disclosed peers, an increase of 0.64 percentage points from the previous quarter and 2.00 percentage points year-on-year [3] - The latest gross profit margin was 43.16%, ranking 18th among disclosed peers, an increase of 4.65 percentage points from the previous quarter but a decrease of 2.90 percentage points year-on-year [3] - The latest return on equity (ROE) was -6.37%, ranking 48th among disclosed peers, a decrease of 6.50 percentage points year-on-year [3] Earnings Per Share and Turnover Ratios - The diluted earnings per share was -0.03 yuan, ranking 41st among disclosed peers, a decrease of 0.03 yuan or 4142.86% year-on-year [3] - The latest total asset turnover ratio was 0.21 times, ranking 25th among disclosed peers, a decrease of 0.03 times or 13.82% year-on-year [3] - The latest inventory turnover ratio was 3.43 times, ranking 23rd among disclosed peers, an increase of 0.16 times, marking five consecutive years of growth, and an increase of 4.91% year-on-year [3]

Group 1 - The company Haocen Medical (SZ 002622) announced the convening of its fifth board meeting on August 28, 2025, which was held in a hybrid format combining in-person and remote voting [1] - The meeting reviewed the proposal regarding the full text and summary of the 2025 semi-annual report [1] Group 2 - The article mentions that over 20,000 applications have been submitted for joining Haidilao, with 41 franchises already opened, indicating strong interest in the brand [1] - The estimated investment required to join Haidilao is around 10 million yuan, which is considered not excessive [1]

格隆汇8月28日丨皓宸医疗(002622.SZ)公布2025年半年度报告，上半年公司实现营业收入3.14亿元，同 比下降17.90%；归属于上市公司股东的净利润-2375.11万元；归属于上市公司股东的扣除非经常性损益 的净利润-2355.85万元；基本每股收益-0.0283元。 ...

皓宸医疗科技股份有限公司 2025 年半年度财务报告 皓宸医疗科技股份有限公司 2025 年半年度财务报告 2025 年 08 月 1 皓宸医疗科技股份有限公司 2025 年半年度财务报告 一、审计报告 半年度报告是否经过审计 □是 否 公司半年度财务报告未经审计。 二、财务报表 财务附注中报表的单位为：元 1、合并资产负债表 编制单位：皓宸医疗科技股份有限公司 2025 年 06 月 30 日 单位：元 | 项目 | 期末余额 | 期初余额 | | --- | --- | --- | | 流动资产： | | | | 货币资金 | 111,862,603.68 | 147,693,180.87 | | 结算备付金 | | | | 拆出资金 | | | | 交易性金融资产 | | | | 衍生金融资产 | | | | 应收票据 | 4,443,525.52 | 9,041,164.44 | | 应收账款 | 27,438,643.26 | 39,169,433.88 | | 应收款项融资 | | | | 预付款项 | 17,400,007.01 | 6,954,032.08 | | 应收保费 | | | | 应 ...

皓宸医疗科技股份有限公司 2025 年半年度非经营性资金占用及其他关联资金往来情况汇总表 单位:万元 | 非经营性资金占用 | 资金占用 | 占用方与上 | 上市公司 | 年 2025 | 年 月占 2025 1-6 | | 年 月 2025 1-6 | | 年 2025 1-6 | | 年 月 2025 6 | 占用形 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | | 方名称 | 市公司的关 | 核算的会 | 期初占用 | 用累计发生金额 | | 占用资金的利 | | 月偿还累计 | 30 | 日占用资 | 成原因 | 占用性质 | | | | 联关系 | 计科目 | 资金余额 | （不含利息） | | 息（如有） | | 发生金额 | | 金余额 | | | | 控股股东、实际控制 | | | | | | | | | | | | | | | 人及其附属企业 | | | | | | | | | | | | | 非经营性占用 | | 小计 | | | | | | | | | ...

证券代码：002622 证券简称：皓宸医疗 公告编号：2025-019 皓宸医疗科技股份有限公司 1、《皓宸医疗科技股份有限公司第五届监事会第十五次会议决议》。 皓宸医疗科技股份有限公司（以下简称"公司"）第五届监事会第十五次会 议于 2025 年 8 月 17 日以电子邮件的形式发出会议通知，会议于 2025 年 8 月 28 日上午 11:00 以现场结合通讯表决方式召开。本次会议由监事会主席刘月先生主 持，会议应参加表决监事 3 人，实际参加表决监事 3 人。本次会议的内容以及召 集、召开的方式、程序均符合《公司法》和《公司章程》的规定。 与会监事经认真审议，通过如下议案： 一、审议通过《关于 2025 年半年度报告全文及摘要的议案》 表决结果：同意 3 票，反对 0 票，弃权 0 票； 表决结果：通过。 经审核，监事会认为董事会编制和审核公司 2025 年半年度报告的程序符合 法律、行政法规和中国证监会的规定，报告内容真实、准确、完整地反映了上市 公司的实际情况，不存在任何虚假记载、误导性陈述或者重大遗漏。 公司《2025 年半年度报告全文》具体内容详见公司指定信息披露网站巨潮 资讯网（www.cni ...

表决情况：同意 7 票，反对 0 票，弃权 0 票； 表决结果：通过。 本议案已经公司审计委员会审议并取得了明确同意的意见。 证券代码：002622 证券简称：皓宸医疗 公告编号：2025-018 皓宸医疗科技股份有限公司 第五届董事会第十五次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 皓宸医疗科技股份有限公司（以下简称"公司"）第五届董事会第十五次会 议于 2025 年 8 月 28 日上午 10:00 以现场结合通讯表决方式召开。召开本次会议 的通知已于 2025 年 8 月 17 日以电话、电子邮件等方式通知了各位董事。本次会 议由董事长陆璐女士主持，会议应参加表决董事 7 名，实际参加表决董事 7 名。 此次会议的召集、召开与表决程序符合《中华人民共和国公司法》和《公司章程》 及相关法律、法规的规定，合法有效。 与会董事经认真审议，通过如下议案： 一、审议通过《关于 2025 年半年度报告全文及摘要的议案》 1、《皓宸医疗科技股份有限公司第五届董事会第十五次会议决议》。 特此公告。 皓宸医疗科技股份有限公司董事会 二〇二五年八月二十八 ...